

**REFERRAL FORM**  
**COVID-19 Outpatient Treatment**  
**Monoclonal Antibody (mAb) Regional Center (MARC)**  
**Phone: (619) 685-2500**

MARC at Palomar Health/Pomerado Pavilion  
15611 Pomerado Road, Suite 545, Poway CA 92064  
Fax: (760) 739-2851

MARC at San Ysidro Health  
391 Oxford Street, Chula Vista, CA 91911  
Fax: (619) 785-3293

**Instructions**

This form may be used by healthcare providers and [medically eligible patients](#) who are making a self-referral to confirm patient mAb treatment eligibility at the MARC. Treatment will be provided regardless of a patient's health insurance or immigration status. Please follow the checklist below.

**Checklist**

- Complete **all sections** below and schedule a patient's appointment by:
  - Calling **(619) 685-2500 OR**
  - Faxing this referral form to the selected treatment site (see above)
- Patients should receive the following materials:
  - [Casirivimab-Imdevimab FDA mAb EUA Fact Sheet for Patients, Parents and Caregivers \(Spanish\)](#)
  - Optional:* A completed copy of this referral form to bring to his or her appointment
- Patients should be reminded that:
  - Wearing a mask is **required** at his or her appointment
  - A photo ID is **required** for check in at the MARC
- Optional:* Fax a copy of the front and back of the patient's insurance card (if applicable) and photo ID

### **Patient Information**

Name (Last, First) \_\_\_\_\_

Preferred Language \_\_\_\_\_

Date of Birth (MM/DD/YYYY) \_\_\_\_\_

Telephone Number \_\_\_\_\_

Home Address \_\_\_\_\_

Date of Symptom Onset \_\_\_\_\_

Date of Positive COVID-19 Test \_\_\_\_\_

Type of COVID-19 Test  PCR  Antigen

Preferred Appointment Time \_\_\_\_\_

Appointments at the MARC at Palomar Health/Pomerado Pavilion are offered seven days a week from 8:00 AM to 6:30 PM.  
Appointments at the MARC at San Ysidro Health are offered seven days a week from 8:00 AM to 5:00 PM.

### **Healthcare Provider Information**

Name \_\_\_\_\_

Practice Name \_\_\_\_\_

Phone Number \_\_\_\_\_

### **Inclusion Criteria**

Patients must meet **ALL** of the following initial **AND** risk factor EUA criteria ([Casirivimab-Imdevimab](#)):

#### **Initial Criteria**

- 12 years of age or older
- Weigh at least 40 kg (88 lbs)
- Positive SARS-CoV-2 test result (PCR or rapid antigen)
- Symptomatic COVID-19 positive outpatient who **DOES NOT** require supplemental oxygen (beyond baseline requirements)
- Symptom onset within the last 10 days (ideally within 72 hours)

#### **Risk Factor Criteria**

- NO** history of allergic reaction to mAb administration
- AT LEAST ONE** of the following risk factors for progressing to severe COVID-19 listed below (FDA EUA criteria for [Casirivimab-Imdevimab](#))
  - Older age (for example age  $\geq 65$  years)

- Obesity or being overweight (for example, adults with BMI >25 kg/m<sup>2</sup>, or if age 12-17, have BMI ≥85<sup>th</sup> percentile for their age and gender based on [CDC Clinical Growth Charts](#))
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or
  - Immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or
  - Hypertension
- Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19))
- Other medical conditions or factors (for example, race or ethnicity) that may also place individual patients at high risk for progression to severe COVID-19

Authorization of these mAb treatments under EUA is not limited to the medical conditions or factors listed above. For additional information on medical conditions and factors associated with increased risk for progression to severe COVID-19, see the CDC's [People with Certain Medical Conditions webpage](#). Healthcare providers should consider the benefits and risks of treatment for an individual patient.